monomethyl fumarate 190 mg

DRUG2 trials

Sponsors

Banner Life Sciences LLC

Conditions

Relapsing Remitting Multiple Sclerosis

Phase 1

Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects

CompletedNCT04570670

Banner Life Sciences LLCRelapsing Remitting Multiple Sclerosis

Start: 2017-01-06End: 2017-02-17Updated: 2022-12-30

Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects

CompletedNCT05181215

Banner Life Sciences LLCRelapsing Remitting Multiple Sclerosis

Start: 2021-05-14End: 2021-08-27Updated: 2022-01-06

Related Papers

Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera<sup>®</sup> (Dimethyl Fumarate).

2021-03-3019 citations